Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 98Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 41Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

Meropenem 7Vancomycin 6pegfilgrastim 5Filgrastim 5Ceftazidime 5pegylated granulocyte colony-stimulating factor 4Cefepime 4Levofloxacin 3Ciprofloxacin 3Amikacin 3Teicoplanin 2Piperacillin, Tazobactam Drug Combination 2Linezolid 2Interleukin 1 Receptor Antagonist Protein 2Anti-Bacterial Agents 2Amoxicillin-Potassium Clavulanate Combination 2ceftolozane, tazobactam drug combination 1Vaccination 1Therapeutics 1Tazobactam 1TKN732 1Surveys and Questionnaires 1Sodium Chloride 1Simvastatin 1Positron Emission Tomography Computed Tomography 1Pneumococcal Vaccines 1Piperacillin 1Ofloxacin 1NF protocol 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Febrile Neutropenia × Bevacizumab × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡